Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von PapaSmurf 

Regeneron Pharmaceuticals Inc. diskutieren

Regeneron Pharmaceuticals Inc.

WKN: 881535 / Symbol: REGN / Name: Regeneron / Aktie / Biotechnologie & medizinische Forschung / Large Cap /

532,90 €
2,24 %

Einschätzung Buy
Rendite (%) -11,67 %
Kursziel 785,87
Veränderung
Endet am 30.04.27

Regeneron Pharmaceuticals (REGN) had its price target lowered by Barclays PLC from $923.00 to $917.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat

Einschätzung Buy
Rendite (%) -0,92 %
Kursziel 735,81
Veränderung
Endet am 18.05.27

Regeneron Pharmaceuticals (REGN) had its price target lowered by Piper Sandler from $875.00 to $855.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat

Einschätzung Buy
Rendite (%) -1,03 %
Kursziel 731,51
Veränderung
Endet am 18.05.27

Regeneron Pharmaceuticals (REGN) had its price target lowered by JPMorgan Chase & Co. from $950.00 to $850.00. They now have an "overweight" rating on the stock.
Ratings data for REGN provided by MarketBeat

Einschätzung Buy
Rendite (%) -1,12 %
Kursziel 669,55
Veränderung
Endet am 18.05.27

Regeneron Pharmaceuticals (REGN) had its price target lowered by Truist Financial Corporation from $796.00 to $778.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat

Einschätzung Buy
Rendite (%) -1,34 %
Kursziel 628,24
Veränderung
Endet am 18.05.27

Regeneron Pharmaceuticals (REGN) had its price target lowered by BMO Capital Markets from $900.00 to $730.00. They now have an "outperform" rating on the stock.
Ratings data for REGN provided by MarketBeat

Einschätzung Buy
Rendite (%) -1,10 %
Kursziel 751,63
Veränderung
Endet am 19.05.27

Regeneron Pharmaceuticals (REGN) had its price target lowered by Canaccord Genuity Group Inc. from $1,057.00 to $875.00. They now have a "buy" rating on the stock.
Ratings data for REGN provided by MarketBeat